The Beauty Health Company (SKIN) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales were $78.8 million, down 19.1% year-over-year, mainly due to weak device (Delivery Systems) sales, especially internationally, but offset by 10.4% growth in consumables and the Hydralock HA Booster launch.

• Gross margin improved to 51.6% from -12.9% in Q3 2023, driven by operational initiatives and the absence of prior year Syndeo Program charges.

• Adjusted EBITDA was $8.1 million, exceeding guidance, with profitability supported by higher gross margin and disciplined expense management.

• Net loss narrowed to $18.3 million from $73.8 million in Q3 2023.

• Strategic actions included centralizing manufacturing in Long Beach, leadership changes, and completion of the Syndeo Program.

Financial highlights

• Gross profit for Q3 was $40.6 million, a significant improvement from a $12.6 million loss in the prior year.

• Adjusted gross margin reached 69.5%, up from 62.5% a year ago, due to lower inventory charges, higher ASPs, and a favorable sales mix.

• Operating expenses decreased 10.6% to $62.2 million; operating loss narrowed to $21.5 million from $82.1 million in Q3 2023.

• Cash and equivalents at quarter-end were $358.9 million, with $156 million deployed YTD to repurchase $192 million of convertible debt.

• Net loss per share was $0.15 (basic and diluted) for Q3 2024.

Outlook and guidance

• Full-year 2024 net sales guidance is $322–$332 million, with Adjusted EBITDA between -$2 million and +$4 million.

• Q4 revenue expected to decline ~21% year-over-year, with growth in the Americas offset by international declines, especially China.

• Management believes liquidity is sufficient for at least the next 12 months, but continues to monitor macroeconomic and credit risks.

• Focus remains on margin expansion and profitability in 2025; more details to be provided in the next earnings call.